ID   PIAS2_RAT               Reviewed;         572 AA.
AC   Q6AZ28; Q9Z177;
DT   07-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2004, sequence version 1.
DT   02-OCT-2024, entry version 151.
DE   RecName: Full=E3 SUMO-protein ligase PIAS2;
DE            EC=2.3.2.-;
DE   AltName: Full=Androgen receptor-interacting protein 3;
DE            Short=ARIP3;
DE   AltName: Full=DAB2-interacting protein;
DE            Short=DIP;
DE   AltName: Full=E3 SUMO-protein transferase PIAS2 {ECO:0000305};
DE   AltName: Full=Msx-interacting-zinc finger protein;
DE   AltName: Full=Protein inhibitor of activated STAT x;
DE   AltName: Full=Protein inhibitor of activated STAT2;
GN   Name=Pias2; Synonyms=Miz1, Piasx;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH AR, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Testis;
RX   PubMed=9920921; DOI=10.1074/jbc.274.6.3700;
RA   Moilanen A.-M., Karvonen U., Poukka H., Yan W., Toppari J., Jaenne O.A.,
RA   Palvimo J.J.;
RT   "A testis-specific androgen receptor coregulator that belongs to a novel
RT   family of nuclear proteins.";
RL   J. Biol. Chem. 274:3700-3704(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   INTERACTION WITH AR; ESR1; ESR2; NR3C1 AND PGR.
RX   PubMed=11117529; DOI=10.1210/mend.14.12.0569;
RA   Kotaja N., Aittomaeki S., Silvennoinen O., Palvimo J.J., Jaenne O.A.;
RT   "ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein
RT   inhibitor of activated STAT) proteins differ in their ability to modulate
RT   steroid receptor-dependent transcriptional activation.";
RL   Mol. Endocrinol. 14:1986-2000(2000).
RN   [4]
RP   INTERACTION WITH NCOA2, AND MUTAGENESIS OF LEU-23; LEU-304; CYS-385 AND
RP   CYS-388.
RX   PubMed=11893729; DOI=10.1074/jbc.m106354200;
RA   Kotaja N., Vihinen M., Palvimo J.J., Jaenne O.A.;
RT   "Androgen receptor-interacting protein 3 and other PIAS proteins cooperate
RT   with glucocorticoid receptor-interacting protein 1 in steroid receptor-
RT   dependent signaling.";
RL   J. Biol. Chem. 277:17781-17788(2002).
RN   [5]
RP   INTERACTION WITH SUMO1; UBE2I AND AR, SUMOYLATION OF AR; JUN AND NCOA2,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-324; LYS-326; LYS-379;
RP   LYS-380; TRP-383; LYS-390; LYS-391; LYS-430 AND LYS-431.
RX   PubMed=12077349; DOI=10.1128/mcb.22.14.5222-5234.2002;
RA   Kotaja N., Karvonen U., Jaenne O.A., Palvimo J.J.;
RT   "PIAS proteins modulate transcription factors by functioning as SUMO-1
RT   ligases.";
RL   Mol. Cell. Biol. 22:5222-5234(2002).
RN   [6]
RP   STAT1 SUMOYLATION.
RX   PubMed=12855578; DOI=10.1182/blood-2002-12-3816;
RA   Ungureanu D., Vanhatupa S., Kotaja N., Yang J., Aittomaeki S., Jaenne O.A.,
RA   Palvimo J.J., Silvennoinen O.;
RT   "PIAS proteins promote SUMO-1 conjugation to STAT1.";
RL   Blood 102:3311-3313(2003).
CC   -!- FUNCTION: Functions as an E3-type small ubiquitin-like modifier (SUMO)
CC       ligase, stabilizing the interaction between UBE2I and the substrate,
CC       and as a SUMO-tethering factor. Plays a crucial role as a
CC       transcriptional coregulation in various cellular pathways, including
CC       the STAT pathway, the p53 pathway and the steroid hormone signaling
CC       pathway. The effects of this transcriptional coregulation,
CC       transactivation or silencing may vary depending upon the biological
CC       context and PIAS2 isoform studied. However, it seems to be mostly
CC       involved in gene silencing. Binds to sumoylated ELK1 and enhances its
CC       transcriptional activity by preventing recruitment of HDAC2 by ELK1,
CC       thus reversing SUMO-mediated repression of ELK1 transactivation
CC       activity (By similarity). Sumoylates PML at'Lys-65' and 'Lys-160' (By
CC       similarity). {ECO:0000250}.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Binds SUMO1 and UBE2I. Interacts with AXIN1, JUN, MDM2, PARK7,
CC       TP53 and TP73 isoform alpha, but not TP73 isoform beta. Interacts with
CC       STAT4 following IL12 and IFN-alpha stimulation of T-cells. Interacts
CC       also with GTF2I, GTF2IRD1, IKFZ1, DAB2 and MSX2, as well as with
CC       several steroid receptors, including ESR1, ESR2, NR3C1, PGR, AR, and
CC       with NCOA2. Sumoylation of a target protein seems to enhance the
CC       interaction. Binds to sumoylated ELK1. Binds DNA, such as CDKN1A
CC       promoter, in a sequence-specific manner. Interacts with PLAG1.
CC       Interacts with KLF8; the interaction results in SUMO ligation and
CC       repression of KLF8 transcriptional activity and of its cell cycle
CC       progression into G(1) phase (By similarity). Interacts with IFIH1/MDA5
CC       (By similarity). Interacts with PML (By similarity). Interacts with
CC       PRDM1 (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:O75928}.
CC   -!- SUBCELLULAR LOCATION: Nucleus speckle {ECO:0000269|PubMed:12077349,
CC       ECO:0000269|PubMed:9920921}. Nucleus, PML body
CC       {ECO:0000250|UniProtKB:O75928}. Nucleus {ECO:0000269|PubMed:9920921}.
CC       Note=Colocalizes at least partially with promyelocytic leukemia nuclear
CC       bodies (PML NBs) (By similarity). Colocalizes with SUMO1 in nuclear
CC       granules (PubMed:12077349). {ECO:0000250|UniProtKB:O75928,
CC       ECO:0000269|PubMed:12077349}.
CC   -!- TISSUE SPECIFICITY: Mainly expressed in testis.
CC       {ECO:0000269|PubMed:9920921}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in spermatogonia and in primary
CC       spermatocytes up to late pachytene stage (at protein level).
CC   -!- DOMAIN: The LXXLL motif is a transcriptional coregulator signature.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:12077349}.
CC   -!- SIMILARITY: Belongs to the PIAS family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF044058; AAD13349.1; -; mRNA.
DR   EMBL; BC078775; AAH78775.1; -; mRNA.
DR   RefSeq; NP_445789.1; NM_053337.1.
DR   AlphaFoldDB; Q6AZ28; -.
DR   SMR; Q6AZ28; -.
DR   BioGRID; 249702; 3.
DR   STRING; 10116.ENSRNOP00000023886; -.
DR   iPTMnet; Q6AZ28; -.
DR   PhosphoSitePlus; Q6AZ28; -.
DR   PaxDb; 10116-ENSRNOP00000023886; -.
DR   GeneID; 83422; -.
DR   KEGG; rno:83422; -.
DR   AGR; RGD:71056; -.
DR   CTD; 9063; -.
DR   RGD; 71056; Pias2.
DR   eggNOG; KOG2169; Eukaryota.
DR   InParanoid; Q6AZ28; -.
DR   OrthoDB; 20246at2759; -.
DR   PhylomeDB; Q6AZ28; -.
DR   Reactome; R-RNO-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-RNO-3232118; SUMOylation of transcription factors.
DR   Reactome; R-RNO-3232142; SUMOylation of ubiquitinylation proteins.
DR   Reactome; R-RNO-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-RNO-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-RNO-4551638; SUMOylation of chromatin organization proteins.
DR   UniPathway; UPA00886; -.
DR   PRO; PR:Q6AZ28; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0016607; C:nuclear speck; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0016605; C:PML body; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0050681; F:nuclear androgen receptor binding; IPI:MGI.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:RGD.
DR   GO; GO:0035259; F:nuclear glucocorticoid receptor binding; IPI:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; ISO:RGD.
DR   GO; GO:0061665; F:SUMO ligase activity; ISO:RGD.
DR   GO; GO:0019789; F:SUMO transferase activity; ISO:RGD.
DR   GO; GO:0003712; F:transcription coregulator activity; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; ISO:RGD.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; IMP:RGD.
DR   GO; GO:0006351; P:DNA-templated transcription; ISO:RGD.
DR   GO; GO:0060766; P:negative regulation of androgen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0050775; P:positive regulation of dendrite morphogenesis; IMP:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:RGD.
DR   GO; GO:0016925; P:protein sumoylation; ISS:UniProtKB.
DR   GO; GO:0060765; P:regulation of androgen receptor signaling pathway; IDA:MGI.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IDA:RGD.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; ISO:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0007283; P:spermatogenesis; IEP:RGD.
DR   CDD; cd16819; SP-RING_PIAS2; 1.
DR   Gene3D; 2.60.120.780; PINIT domain; 1.
DR   Gene3D; 1.10.720.30; SAP domain; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR023321; PINIT.
DR   InterPro; IPR038654; PINIT_sf.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   InterPro; IPR004181; Znf_MIZ.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10782:SF12; E3 SUMO-PROTEIN LIGASE PIAS2; 1.
DR   PANTHER; PTHR10782; ZINC FINGER MIZ DOMAIN-CONTAINING PROTEIN; 1.
DR   Pfam; PF14324; PINIT; 1.
DR   Pfam; PF02891; zf-MIZ; 1.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SAP domain; 1.
DR   PROSITE; PS51466; PINIT; 1.
DR   PROSITE; PS50800; SAP; 1.
DR   PROSITE; PS51044; ZF_SP_RING; 1.
PE   1: Evidence at protein level;
KW   DNA-binding; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..572
FT                   /note="E3 SUMO-protein ligase PIAS2"
FT                   /id="PRO_0000218978"
FT   DOMAIN          11..45
FT                   /note="SAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00186"
FT   DOMAIN          134..299
FT                   /note="PINIT"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00799"
FT   ZN_FING         331..412
FT                   /note="SP-RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   REGION          467..473
FT                   /note="SUMO1-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          523..572
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           19..23
FT                   /note="LXXLL motif"
FT   MOTIF           484..492
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        535..572
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         362
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   BINDING         364
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   BINDING         385
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   BINDING         388
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00452"
FT   MOD_RES         476
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   MOD_RES         477
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   MOD_RES         478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   MOD_RES         499
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C5D8"
FT   CROSSLNK        46
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        249
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        430
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        435
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        443
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        452
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        489
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   CROSSLNK        502
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0000250|UniProtKB:O75928"
FT   MUTAGEN         23
FT                   /note="L->A: Loss of enhancement of AR and NR3C1-dependent
FT                   transactivation; no effect on interaction with AR and
FT                   NR3C1; when associated with A-305."
FT                   /evidence="ECO:0000269|PubMed:11893729"
FT   MUTAGEN         304
FT                   /note="L->A: Loss of enhancement of AR and NR3C1-dependent
FT                   transactivation; no effect on interaction with AR and
FT                   NR3C1; when associated with A-23."
FT                   /evidence="ECO:0000269|PubMed:11893729"
FT   MUTAGEN         324
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-326."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         326
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-324."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         379
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-380."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         380
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-379."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         383
FT                   /note="W->A: Loss of promotion of JUN sumoylation; no loss
FT                   of interaction with SUMO1 and UBE2I."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         385
FT                   /note="C->S: Loss of NCOA2-binding; when associated with S-
FT                   388."
FT                   /evidence="ECO:0000269|PubMed:11893729"
FT   MUTAGEN         388
FT                   /note="C->S: Loss of NCOA2-binding; when associated with S-
FT                   385."
FT                   /evidence="ECO:0000269|PubMed:11893729"
FT   MUTAGEN         390
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-391."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         391
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-390."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         430
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-431."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   MUTAGEN         431
FT                   /note="K->R: No effect on auto-sumoylation; when associated
FT                   with R-430."
FT                   /evidence="ECO:0000269|PubMed:12077349"
FT   CONFLICT        50
FT                   /note="T -> S (in Ref. 1; AAD13349)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        320
FT                   /note="R -> K (in Ref. 1; AAD13349)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   572 AA;  63431 MW;  E107F8B26403D2FB CRC64;
     MADFEELRNM VSSFRVSELQ VLLGFAGRNK SGRKHDLLMR ALHLLKSGCT PAVQIKIREL
     YRRRYPRTLE GLSDLSTIKS SVFSLDGSSS PVEPDLAVAG IHSLPSTSIA PHSPSSPVAS
     VLLQDTKPTF EMQQPSPPIP PVHPDVQLKT LPFYDVLDVL IKPTSLVQSS IQRFQEKFFI
     FALTPQQVRE ICISRDFLPG GRRDYTVQVQ LRLCLAETSC PQEDNYPNSL CIKVNGKLFP
     LPGYAPPPKN GIEQKRPGRP LNITSLVRLS SAVPNQISIS WASEIGKNYS MSVYLVRQLT
     SAMLLQRLKM KGIRNPDHSR ALIKEKLTAD PDSEIATTSL RVSLMCPLGK MRLTIPCRAV
     TCTHLQCFDA ALYLQMNEKK PTWICPVCDK KAAYESLILD GLFMEILNDC SDVDEIKFQE
     DGSWCPMRPK KEAMKVTSQP CTKVESSSVF SKPCSVTVAS DASKKKIDVI DLTIESSSDE
     EEDPPAKRKC IFMSETQSSP TKGVLMYQPS SVRVPSVTSV DPAAIPPSLT DYSVPFHHTP
     VSSMSSDLPG EQRRNDINNE VQLGTSSDTV QQ
//
